Literature DB >> 29400667

Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease.

P Hemachandra Reddy1,2,3,4,5,6,7, Maria Manczak1, XiangLing Yin1, Arubala P Reddy1,8.   

Abstract

The purpose of our study was to determine the synergistic protective effects of mitochondria-targeted antioxidant SS31 and mitochondria division inhibitor 1 (Mdivi1) in Alzheimer's disease (AD). Using biochemical methods, we assessed mitochondrial function by measuring the levels of hydrogen peroxide, lipid peroxidation, cytochrome c oxidase activity, mitochondrial ATP, and GTPase Drp1 enzymatic activity in mutant AβPP cells. Using biochemical methods, we also measured cell survival and apoptotic cell death. Amyloid-β (Aβ) levels were measured using sandwich ELISA, and using real-time quantitative RT-PCR, we assessed mtDNA (mtDNA) copy number in relation to nuclear DNA (nDNA) in all groups of cells. We found significantly reduced levels of Aβ40 and Aβ42 in mutant AβPP cells treated with SS31, Mdivi1, and SS31+Mdivi1, and the reduction of Aβ42 levels were much higher in SS31+Mdivi1 treated cells than individual treatments of SS31 and Mdivi1. The levels of mtDNA copy number and cell survival were significantly increased in SS31, Mdivi1, and SS31+Mdivi1 treated mutant AβPP cells; however, the increased levels of mtDNA copy number and cell survival were much higher in SS31+Mdivi1 treated cells than individual treatments of SS31 and Mdivi1. Mitochondrial dysfunction is significantly reduced in SS31, Mdivi1, and SS31+Mdivi1 treated mutant AβPP cells; however, the reduction is much higher in cells treated with both SS31+Mdvi1. Similarly, GTPase Drp1 activity is reduced in all treatments, but reduced much higher in SS31+Mdivi1 treated cells. These observations strongly suggest that combined treatment of SS31+Mdivi1 is effective than individual treatments of SS31 and Mdivi1. Therefore, we propose that combined treatment of SS31+Mdivi1 is a better therapeutic strategy for AD. Ours is the first study to investigate combined treatment of mitochondria-targeted antioxidant SS31 and mitochondrial division inhibitor 1 in AD neurons.

Entities:  

Keywords:  Amyloid-β; mitochondria-targeted antioxidant SS31; mitochondrial biogenesis; mitochondrial division inhibitor 1; mitochondrial dynamics; mitochondrial dysfunction; mitochondrial fission; synergistic protective effects

Mesh:

Substances:

Year:  2018        PMID: 29400667      PMCID: PMC5884714          DOI: 10.3233/JAD-170988

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  58 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Dynasore, a cell-permeable inhibitor of dynamin.

Authors:  Eric Macia; Marcelo Ehrlich; Ramiro Massol; Emmanuel Boucrot; Christian Brunner; Tomas Kirchhausen
Journal:  Dev Cell       Date:  2006-06       Impact factor: 12.270

3.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

4.  A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity.

Authors:  Xin Qi; Nir Qvit; Yu-Chin Su; Daria Mochly-Rosen
Journal:  J Cell Sci       Date:  2012-12-13       Impact factor: 5.285

5.  Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington's disease.

Authors:  Maria Manczak; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2015-10-12       Impact factor: 6.150

Review 6.  Mitochondria-targeted peptide antioxidants: novel neuroprotective agents.

Authors:  Hazel H Szeto
Journal:  AAPS J       Date:  2006-08-18       Impact factor: 4.009

7.  Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer's disease: implications for neuroprotection and lifespan extension.

Authors:  Peizhong Mao; Maria Manczak; Marcus J Calkins; Quang Truong; Tejaswini P Reddy; Arubala P Reddy; Ulziibat Shirendeb; Herng-Hsiang Lo; Peter S Rabinovitch; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2012-04-05       Impact factor: 6.150

8.  Role of mitochondrial fission in neuronal injury in pilocarpine-induced epileptic rats.

Authors:  X Qiu; L Cao; X Yang; X Zhao; X Liu; Y Han; Y Xue; H Jiang; Z Chi
Journal:  Neuroscience       Date:  2013-04-15       Impact factor: 3.590

9.  Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice.

Authors:  Virginie Rhein; Xiaomin Song; Andreas Wiesner; Lars M Ittner; Ginette Baysang; Fides Meier; Laurence Ozmen; Horst Bluethmann; Stefan Dröse; Ulrich Brandt; Egemen Savaskan; Christian Czech; Jürgen Götz; Anne Eckert
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-06       Impact factor: 11.205

Review 10.  Targeting antioxidants to mitochondria by conjugation to lipophilic cations.

Authors:  Michael P Murphy; Robin A J Smith
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

View more
  26 in total

1.  Protective effects of BACE1 inhibitory ligand molecules against amyloid beta-induced synaptic and mitochondrial toxicities in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; Xiangling Yin; Maria Manczak; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2020-01-01       Impact factor: 6.150

Review 2.  Small molecules as therapeutic drugs for Alzheimer's disease.

Authors:  Darryll M A Oliver; P Hemachandra Reddy
Journal:  Mol Cell Neurosci       Date:  2019-03-12       Impact factor: 4.314

Review 3.  Defective mitophagy in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; P Hemachandra Reddy
Journal:  Ageing Res Rev       Date:  2020-10-03       Impact factor: 10.895

4.  The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis.

Authors:  Joshua A Grosser; Rachel L Fehrman; Dennis Keefe; Martin Redmon; Robert W Nickells
Journal:  BMC Res Notes       Date:  2021-05-22

5.  Peptide Szeto‑Schiller 31 ameliorates doxorubicin‑induced cardiotoxicity by inhibiting the activation of the p38 MAPK signaling pathway.

Authors:  Li Zhang; Mengwen Feng; Xuejun Wang; Hao Zhang; Jingjing Ding; Zijie Cheng; Lingmei Qian
Journal:  Int J Mol Med       Date:  2021-03-02       Impact factor: 4.101

Review 6.  Too much death can kill you: inhibiting intrinsic apoptosis to treat disease.

Authors:  Kaiming Li; Mark F van Delft; Grant Dewson
Journal:  EMBO J       Date:  2021-05-26       Impact factor: 14.012

7.  Mitochondrial PKA Is Neuroprotective in a Cell Culture Model of Alzheimer's Disease.

Authors:  Tania Das Banerjee; Kelly Reihl; Maryann Swain; Mariana Torres; Ruben K Dagda
Journal:  Mol Neurobiol       Date:  2021-02-23       Impact factor: 5.682

Review 8.  Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease.

Authors:  Chanchal Sharma; Sehwan Kim; Youngpyo Nam; Un Ju Jung; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

Review 9.  The Influence of Mitochondrial Dynamics and Function on Retinal Ganglion Cell Susceptibility in Optic Nerve Disease.

Authors:  Nicole A Muench; Sonia Patel; Margaret E Maes; Ryan J Donahue; Akihiro Ikeda; Robert W Nickells
Journal:  Cells       Date:  2021-06-25       Impact factor: 6.600

10.  Mitochondria-Targeted Small Peptide, SS31 Ameliorates Diabetes Induced Mitochondrial Dynamics in Male TallyHO/JngJ Mice.

Authors:  Jasvinder Singh Bhatti; Kavya Thamarai; Ramesh Kandimalla; Maria Manczak; Xiangling Yin; Subodh Kumar; Murali Vijayan; P Hemachandra Reddy
Journal:  Mol Neurobiol       Date:  2020-10-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.